The report itself is scheduled for release in October 2026, and its scope is unusually broad for this kind of analysis. Rather than simply cataloging list prices at launch, the 2026 edition will examine launch price trends across four full years of FDA approvals, spanning 2022 through 2025. That longitudinal window matters. A single year of launch prices can be distorted by a handful of high-profile gene therapies or cancer treatments; four years of data allow analysts to distinguish genuine market-wide trends from statistical noise, and to see whether the trajectory of introductory prices is rising faster than inflation, faster than the economy as a whole, or in line with the added clinical value that new drugs actually deliver.

The access component is arguably the more novel half of the project. ICER and West Health plan to combine real-world pharmacy and medical claims data with payer coverage policies and direct patient surveys, building a picture of what happens after a drug is approved and priced. List price is only the opening move in a complicated negotiation between manufacturers, insurers, pharmacy benefit managers, and patients. A drug may carry a headline price of hundreds of thousands of dollars a year yet be broadly covered with manageable cost-sharing, or a nominally cheaper medicine may sit behind restrictive prior-authorization requirements, step therapy protocols, or specialty-tier coinsurance that effectively locks patients out. By triangulating claims data, coverage policy documents, and patient-reported experience, the report aims to measure that second, less visible dimension of the market.

ICER published the first edition of the Launch Price and Access Report in 2025, and its findings signaled a significant jump in launch prices that outpaced both inflation and gross domestic product growth. That debut established the methodology the partnership will now extend: tracking the introductory prices of newly approved treatments and comparing them against benchmarks of economic growth and the clinical benefit those treatments provide. The 2025 report’s central finding, that launch prices were climbing well beyond general economic measures, set the stage for the question the 2026 edition will pursue: whether that pattern persisted through 2025, and whether patient access kept pace, deteriorated, or held steady as prices rose.

The institutional logic of the partnership is straightforward. ICER brings the analytical machinery of comparative effectiveness review, a framework it has refined over more than a decade of assessing drugs against clinical evidence and assigning them value-based price benchmarks. West Health brings a policy focus sharpened by years of research on healthcare costs, particularly as they bear on older adults, along with the polling infrastructure of the West Health-Gallup Center on Healthcare in America. Together, the two organizations are positioning the annual report as a recurring, independent yardstick for a market that has historically lacked one. There is no official government publication that systematically tracks launch prices of newly approved drugs against their clinical value; the field has relied on academic analyses and nonprofit reports to fill that gap.

The urgency behind the collaboration is documented in the West Health-Gallup Center’s State of the States 2025 report on healthcare in America. According to that survey, one in five Americans, a record high of 20 percent, said they or someone in their household could not afford prescription medications in the previous three months. Nearly one in three reported skipping a needed medical procedure or test within the past year because of cost. Almost half of adults said they worry they will not be able to afford necessary healthcare services next year. Those figures describe a population for whom the price of a new medicine is not an abstract policy debate but a monthly arithmetic of refills, rent, and groceries.

Leadership at both organizations framed the partnership in terms of that lived reality. Sarah K. Emond, ICER’s president and chief executive officer, said the institute is proud to work with a partner that shares its mission of addressing access and affordability challenges for patients, and that together the organizations will provide an independent analysis of launch price trends over the past four years while assessing patient access to newly launched medicines. Timothy Lash, president and chair of the West Health Policy Center, offered a sharper formulation of the problem. Prescription drugs, he noted, are a key tool for enabling healthy aging, but high prices continue to put needed treatments out of reach for far too many Americans, including older adults. New drugs should improve people’s health, he argued, and the financial reward for developing them should reflect those improvements.

Lash’s comment gestures at the economic theory that underpins ICER’s entire enterprise: the idea that a drug’s price should be proportional to the health it produces. In a well-functioning market, value and price track each other, and the promise of reward drives investment toward the innovations that deliver the greatest benefit. When launch prices detach from measured clinical value, the incentive structure warps. Manufacturers are rewarded for prices that bear little relation to therapeutic advance, payers respond with tighter utilization management, and patients encounter a coverage landscape that grows more labyrinthine each year. Understanding the value of new drugs, as Lash put it, is critical for developing policies that ensure affordable access while also signaling to innovators that the best drugs get the best prices. The annual report is designed to supply exactly that understanding, year after year, in a form that policymakers, payers, and researchers can cite and compare over time.

The methodological stakes are considerable. Claims data reveal what patients actually filled and what they actually paid, capturing the discounts, rebates, and coverage decisions that never appear on a list price. Payer coverage policies reveal the formal architecture of access, including which drugs land on preferred tiers and which require documented failure of cheaper alternatives first. Patient surveys add the dimension neither dataset can supply: whether people delayed filling a prescription, cut pills in half, or abandoned a therapy at the pharmacy counter. No single source tells the whole story, and the report’s triangulation of all three is what distinguishes it from the price-tracking exercises that dominate pharmaceutical market coverage.

For the pharmaceutical industry, the annualized report creates a new layer of public accountability. Launch prices are set in a period of deliberate opacity, before rebate negotiations are visible and before utilization data accumulate, and manufacturers have long defended introductory prices as reflecting anticipated value and development costs. A recurring, independent analysis that publishes those prices alongside measures of patient access will make it harder for the market’s opening moves to escape scrutiny, and easier for legislators, insurers, and patient advocates to argue from evidence rather than anecdote. Whether the 2026 findings show the price trajectory of 2022 through 2025 bending toward value or continuing to outrun it, the report will establish a baseline that future years can be measured against, which is precisely what an annual series is built to do. The complete report timeline is available through ICER’s assessment page, and the findings, when they arrive in October, will land in the middle of an ongoing national argument about what Americans should pay for the newest medicines, and who gets left behind when the answer is too high.

Subject of Research: Annual analysis of launch prices and patient access for newly approved FDA drugs

Article Title: ICER, West Health partner on annual new drug Launch Price and Access Report

Article References: ICER, West Health partner on annual new drug Launch Price and Access Report. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ICER, West Health, drug pricing, FDA approvals, patient access, prescription drug costs, health policy, launch prices, pharmaceutical industry, healthcare affordability, drug value assessment, Gallup survey

The headline numbers are striking. Between 1991 and 2024, the overall cancer death rate in the United States fell by 35 percent, an achievement the report attributes to reductions in smoking rates combined with advances in prevention, early detection, and treatment. That decline translates into 4.8 million fewer cancer deaths over the period. Survival gains are increasingly extending even to patients with advanced and metastatic disease: the five-year relative survival rate for distant-stage cancers of all types has more than doubled over the past three decades, rising from 17 percent in the mid-1990s to 36 percent during 2016 to 2022. Those figures, the report argues, are the direct product of sustained federal investment in the National Institutes of Health, the National Cancer Institute, the Food and Drug Administration, and the Centers for Disease Control and Prevention.

The regulatory pipeline tells a similar story of momentum. From July 1, 2025, to June 30, 2026, the FDA approved 11 new anticancer therapeutics, several of which marked historic firsts. Among them was the first molecularly targeted therapy for a rare, aggressive brain tumor driven by a specific genetic alteration, and the first approval of a proteolysis-targeting chimera, a novel class of drug that hijacks the cell’s own protein degradation machinery to destroy cancer cells, indicated for patients with breast cancer. The agency also greenlit the first immune checkpoint inhibitor for ovarian cancer and the first chimeric antigen receptor T-cell therapy for patients with marginal zone lymphoma, extending a living-drug approach once confined to a handful of blood cancers.

Beyond new molecules, the FDA expanded the uses of five previously approved anticancer therapeutics and cleared a series of devices and tools that signal where clinical care is heading. These included a wearable, noninvasive device for treating pancreatic cancer, an at-home human papillomavirus self-collection kit designed to widen access to cervical cancer screening, and several artificial intelligence-based tools intended to improve the early detection and diagnosis of cancers. Taken together, the approvals sketch a regulatory environment increasingly receptive to technologies that move diagnosis out of the clinic and into patients’ homes and that embed computational analysis into routine imaging and pathology.

Artificial intelligence features prominently in the report’s survey of new frontiers. Researchers have recently combined AI with advanced spatial imaging technologies to generate high-resolution maps of tumors, revealing how cancer and immune cells are organized and interact within the tumor microenvironment, knowledge that could guide the design of more effective immunotherapies. In drug development, one recently described AI model screened approximately 10,000 human proteins against more than 500 million compounds, identifying more than 2 million candidate molecules for further study, a scale of exploration unattainable through conventional laboratory screening alone. The report also notes that AI is improving the interpretation of routine medical images and the analysis of complex digital pathology slides, capabilities reflected in the recent FDA approvals of AI-assisted devices, and that AI-driven tools are helping clinicians predict outcomes, personalize treatment plans, and design better clinical trials, while potentially easing burnout among health care providers.

Cancer vaccines, long a tantalizing but elusive goal, are described as gaining real clinical traction. A small individualized pancreatic cancer vaccine trial has produced durable remissions in patients, including Donna Gustafson, one of several patients whose personal stories are woven through the report. In melanoma, patients with high-risk disease who received an individualized mRNA neoantigen vaccine alongside immunotherapy after surgery experienced sustained improvements in recurrence-free and distant metastasis-free survival compared with immunotherapy alone. For early-stage triple-negative breast cancer, an individualized mRNA vaccine generated durable neoantigen-specific T-cell responses, with most patients remaining relapse-free for up to six years after vaccination. A preventive strategy is also under exploration: an mRNA-based vaccine called Nous-209, designed to provoke immune responses against cells carrying Lynch syndrome-associated mutations, was found in a small trial to be safe, free of serious side effects, and capable of triggering a strong, durable immune response in people with the inherited condition.

The report also examines a question now hovering over primary care: whether the hugely popular GLP-1 weight loss drugs might reduce cancer risk. The evidence is genuinely mixed. One recent study found that semaglutide, sold as Ozempic and Wegovy, was associated with a 12 percent reduction in obesity-related cancer risk. A separate study of individuals with type 2 diabetes found that GLP-1 use was associated with a 40 percent lower risk of esophageal cancer and a 46 percent lower risk of colorectal cancer compared with insulin therapy, and other analyses suggest possible reductions in the risk of skin, breast, prostate, hematologic, and some gynecologic cancers. Yet a large review of 48 clinical trials involving more than 94,000 participants treated with GLP-1s found no significant reduction in the overall risk of obesity-related cancers, and some studies point in the opposite direction: liraglutide use was associated with a 70 percent increased risk of thyroid cancer and a 62 percent increased risk of respiratory cancer. The report’s verdict is cautious: the preventive role of these drugs, while promising, requires further investigation.

Against the progress, the report sets a sobering accounting of the disease’s continuing burden. In 2026, an estimated 2.1 million new cancer cases will be diagnosed in the United States, and more than 626,000 people will die from cancer. By 2050, annual new cases are projected to surpass 2.5 million, a 19 percent increase. Survival remains starkly unequal across tumor types: between 2016 and 2022, five-year relative survival was 13.7 percent for pancreatic cancer and just 6.6 percent for glioblastoma, an aggressive brain cancer, compared with 91.9 percent for female breast cancer and 98.2 percent for prostate cancer. The report also flags the rise of early-onset cancers, diagnosed in people aged 18 to 49, as a pressing public health concern. Globally, cancer incidence among people under 50 increased by nearly 80 percent between 1990 and 2019, with gastrointestinal cancers such as colorectal, stomach, and esophageal cancers contributing disproportionately. Researchers cite overlapping drivers including rising obesity, sedentary lifestyles, greater exposure to environmental pollutants, and shifts in dietary patterns.

The economic stakes are equally large. Direct costs of cancer care in the United States, many borne by patients themselves, were estimated at more than $236 billion in 2020, and one analysis cited in the report projects that cancer will cost the U.S. economy $5.3 trillion over the next three decades once indirect costs and lost productivity are included. It is against that backdrop that the AACR issues its policy demands. Most urgently, the organization calls on Congress to permanently block a proposed Office of Management and Budget rule, Regulation for Federal Financial Assistance, which the report warns would inject political considerations into funding decisions and broaden agencies’ authority to terminate grants for reasons unrelated to scientific merit. Bipartisan action has blocked the rule through December 11, 2026, but the report argues a temporary delay is not a lasting solution.

The Call to Action lays out specific asks: at least $51.303 billion for the NIH and at least $7.999 billion for the NCI in fiscal year 2027; protection of the cancer research workforce; preservation of scientific merit as the sole foundation of federal funding decisions; safeguards for active research awards and clinical trials; protection of researchers’ ability to publish and share findings; and risk-based, proportionate oversight of international collaboration. It further urges strengthening the FDA’s capacity to translate discoveries into patient benefits, sustaining evidence-based public health programs, modernizing interoperable data infrastructure, and removing barriers to prevention, screening, clinical trial participation, and survivorship care. AACR President Keith Flaherty, a physician-scientist who chaired the report’s steering committee, said advances in genomics, immunology, and artificial intelligence have given researchers more insight than ever into the complexities of cancer and are enabling treatments that precisely match each patient’s disease. Chief Executive Officer Margaret Foti added that decades of robust federal investment have transformed patient care and saved millions of lives, and that only by sustaining meritorious research free of political interference will the next generation of lifesaving breakthroughs emerge.

Subject of Research: Annual assessment of cancer research progress, FDA approvals, emerging technologies, and federal funding policy

Article Title: AACR releases annual cancer progress report highlighting promising advances for patients

Article References: AACR releases annual cancer progress report highlighting promising advances for patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: AACR, cancer progress report, FDA approvals, cancer mortality, immunotherapy, cancer vaccines, mRNA vaccines, artificial intelligence, GLP-1 receptor agonists, early-onset cancers, NIH funding, cancer screening